Results of the Phase II TITAN study of caplacizumab in patients with aTTP

Dr Marie Scully (University College Hospital, London), Dr Flora Peyvandi (University of Milan, Milan) and Dr Spero Cataland (Ohio State University, Columbus) discuss the TITAN study results recently published in the NEJM. Key investigators from the landmark Phase II TITAN study describe the novel selective anti-von Willebrand Factor Nanobody®, caplacizumab, and discuss the importance of its demonstrated benefits in the worldwide trial for patients with acquired thrombotic thrombocytopenic purpura (aTTP). Inducing significant reductions in both time to platelet count normalisation and recurrences while on treatment, investigators describe how caplacizumab has the potential to become an important new component in the standard of care for patients with aTTP.

Share this video